Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
American Journal of Health-System Pharmacy, Vol 61, Issue 18, 1950-1955
Copyright © 2004 by American Society of Health-System Pharmacists

Articles

ASHP Therapeutic Position Statement on the Use of Low-Molecular-Weight Heparins for Adult Outpatient Treatment of Acute Deep-Vein Thrombosis


Outpatient treatment of DVT with LMWHs offers the opportunity to dramatically reduce the cost of treating DVT and improve the quality of life without compromising clinical outcomes. Given the choice, most patients are willing to be treated at home and are comfortable with or willing to accept the idea of giving themselves injections of LMWHs. Establishing comprehensive outpatient treatment guidelines is important to ensure that adequate support is provided by the anticoagulation provider. Pharmacists have assumed lead roles in developing and maintaining successful outpatient DVT treatment programs. Because of the safety, effectiveness, and potential savings associated with treating patients with acute DVT in the outpatient setting, ASHP encourages health care professionals to become or remain actively involved in the development and documentation of innovative outpatient DVT treatment programs. These programs will also facilitate the use of newer antithrombotic agents as they become available and receive approval for outpatient DVT treatment.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
J. B. Groce
Initial management of deep venous thrombosis in the outpatient setting
Am. J. Health Syst. Pharm., May 1, 2008; 65(9): 866 - 874.
[Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. Nishioka and S. Goodin
Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival
Journal of Oncology Pharmacy Practice, June 1, 2007; 13(2): 85 - 97.
[Abstract] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Goodin
Selecting an anticoagulant for recurrent venous thromboembolism in cancer
Am. J. Health Syst. Pharm., November 15, 2005; 62(22_Supplement_5): S10 - S13.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society of Health-System Pharmacists.